Dr Ibáñez and Dr Arruga will attend the 11th Symposium on Controversies in Ophthalmology

Dr Ibáñez and Dr Arruga will attend the 11th Symposium on Controversies in Ophthalmology

Dr Núria Ibáñez, responsible for the Department of Orbit and Oculoplasty at Institut Català de Retina, will attend on 19th February the IX Symposium on Controversies in Ophthalmology, chaired by Dr Jordi Arruga, Head of ICR Department of Neurophthalmology and by Dr. Manel Quintana.

The symposium’s 11th edition will be held at Hospital Universitari de Bellvitge and will gather professionals in Ophthalmology from all over Spain, with the aim of debating innovative subjects within the area of Medical and Surgical Diagnostic of Eye Diseases.

The symposium will begin with an opening ceremony at 8:45 h lead by Dr Rafael Máñez. The morning session will deal with subjects such as Anophthalmic cavities: the use of surgical pearls and management of orbital volume, as well as Postoperative management and complications in filtering surgery.

Dr Ibáñez will participate in the round table held at 13:30 h at the beginning of afternoon’s session which will deal with Guidance to diagnosis and therapeutic management in palpebral malposition. The round table will be chaired by Dr. Maravilla Abias.

The last round table will address the different kinds of glaucoma surgeries and which one to choose. The event will come to an end around 16:30 with the closing ceremony.

Post your comment

In accordance with the provisions of the General Data Protection Regulation (REGULATION (EU) 2016/679), the following information about the processing of personal data is disclosed to you.

Responsible: Institut Català de la Retina, S.L., Institut Català de Cirurgia refractiva, S.L. (from now on ICR)

Representative of Data Protection Contact: C/Pau Alcover nº 67 08017 Barcelona – rgpd@icrcat.com

Aim: The purpose of the treatment is to manage the information you provide us and after having your consent, publish the testimonial on our website.

Legitimization: The legal basis for the present treatment is the request made by you and having your consent.

Recipients: The recipients of the information are the departments and delegations in which ICR is organized, in part or in its entirety. It will not be communicated to third parties.

Rights: At any time, you can exercise your rights of access, rectification, deletion, opposition, limitation of treatment and / or portability of data by writing to the RPD Representative of Data Protection at the address provided in contact. You can also revoke consents to other treatments. You can also request more information from the RPD about the treatments performed.
In the event that you consider that your rights have been violated, you can submit a claim to the competent Data Protection Control Authority.

For all purposes, the user accepts that the opinion expressed will be exclusively his /her responsibility. The user assumes under his / her exclusive responsibility the damages or harms that may derive from it.
ICR will not be responsible for the accuracy, quality, reliability, correctness, morality and legality of the data, information or opinions published by users.
ICR reserves the right not to publish all opinions of users.
The user is solely responsible of his /her username. ICR will not be responsible for the illegal use or for illicit purposes that other users can make of this user name.

Preservation: The collected data will be kept during the time required for the requested management, for at most 30 days.

ICR Ganduxer Headquarters

c/Ganduxer,117
08022 Barcelona

ICR Pau Alcover

C. Pau Alcover 67
08017 Barcelona

ICR Terrassa

C. del Nord, 77
08221 Terrassa

Clínica Bonanova Surgical Center

Passeig Bonanova, 22
08022 Barcelona

Clinica Bonanova Tests and Treatments

c/ Mandri, 63
08022 Barcelona

ICR Service at Clínica Ntra. Sra. del Remei

c/ de l'Escorial,148
08024 Barcelona
This website uses cookies in order to collect statistical information regarding navigation. If you keep on surfing this website, it shall be deemed to have acknowledged its use. More information.